Cizzle Biotechnology Expands Groundbreaking Early Lung Cancer Test to the Caribbean

17 December 2024, London: Cizzle Biotechnology, a UK-based diagnostics developer, has announced a significant expansion of its exclusive licensing and partnership agreement with Cizzle Bio Inc. (BIO) to deliver its pioneering CIZ1B biomarker test for early lung cancer detection to the Caribbean market. The agreement now extends beyond the USA and Canada to include 14 sovereign Caribbean nations and the Cayman Islands, highlighting Cizzle’s commitment to global accessibility for its life-saving technology.   Transforming Early Cancer Detection Cizzle’s proprietary CIZ1B biomarker test represents a groundbreaking advancement in non-invasive blood screening for early-stage lung cancer. By detecting a specific variant of the CIZ1 protein that is highly correlated with early-stage lung cancer, the test offers a simple yet revolutionary approach to improving survival rates through early diagnosis. Early detection remains the most impactful tool for saving lives, with patients diagnosed in the initial stages having the best chance for curative treatment and long-term survival. This strategic expansion brings critical early-detection technology to an underserved region, while also enriching cancer research with diverse population data.   Key Highlights:

• Market Expansion: Exclusive rights now cover 14 sovereign Caribbean nations and the Cayman Islands.
• Revenue Milestone: BIO to advance US$500,000 in royalty payments by July and September 2025, ahead of the original January 2026 schedule.
• First Clinical Partner: Agreement secured with a CAP-accredited laboratory to register CIZ1B as a CLIA-accredited Laboratory Developed Test (LDT) by January 2025.
• Full product launch: scheduled for April 2025
• Enhanced Accessibility: The Caribbean’s diverse population of nearly 45 million people will benefit from early-stage cancer screening, improving representation in clinical datasets.

Allan Syms, Executive Chairman of Cizzle Biotechnology, commented: “We are thrilled to deepen our partnership with BIO and expand our footprint into the Caribbean. This strategic move aligns with our mission to deliver cost-effective, early-detection diagnostics to underserved regions. Signing their first CAP-accredited laboratory agreement is a significant milestone, and we look forward to achieving CLIA accreditation and commercial launch next year.” Bill Behnke, Chairman and CEO of BIO, added: “Our focus remains on saving lives through early cancer detection. Expanding our agreement to the Caribbean reflects strong interest from our investors and healthcare partners in the region. With our first CAP-accredited laboratory agreement secured, we are on track to achieve CLIA accreditation in January 2025 and commercial launch in April. This partnership also paves the way for additional diagnostic capabilities for other cancers, widening our impact and customer base.”   Driving Global Impact This expanded partnership reinforces Cizzle Biotechnology’s mission to reduce cancer mortality and improve healthcare efficiency through early detection. By extending access to the Caribbean, the collaboration not only addresses underserved populations but also enriches clinical datasets and drives commercial growth, solidifying Cizzle's leadership in early lung cancer diagnostics.   Building strong relationships with clinicians, hospitals, and cancer centres across North America and the Caribbean, this partnership is poised to deliver transformative outcomes:

• Improve early cancer detection rates and reduce premature cancer deaths.
• Enhance patient survival outcomes and overall quality of life.
• Increase ethnic diversity in cancer research, creating more representative datasets.
• Drive sustained revenue growth through market expansion and commercialisation.

With commercial launch on the horizon, this collaboration accelerates Cizzle’s mission to revolutionise global cancer diagnostics. Together, Cizzle Biotechnology and BIO are making early, accessible, and accurate cancer screening a reality—saving lives and addressing unmet clinical needs on a global scale.